Last reviewed · How we verify

NCT06116721

Evaluation of APOL1 Gene Variants in Kidney Donors and Their Impact on Long-term Renal Function in Donors and Recipients

Status unknown Last updated 28 February 2024
What this trial tests

trial in Kidney Diseases in 2,450 participants. Status unknown.

Timeline
15 October 2023
Primary endpoint
31 October 2024
30 November 2025

Quick facts

Lead sponsorHospital do Rim e Hipertensão
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment2,450
Start date15 October 2023
Primary completion31 October 2024
Estimated completion30 November 2025
Sites1 location across Brazil

Conditions studied

Sponsor

Hospital do Rim e Hipertensão

Who can join

Eligibility, any sex, with Kidney Diseases or Transplant Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of the frequency of APOL1 gene variants in kidney donors and the impact of these variants on the long-term renal function of kidney transplant donors and recipients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Kidney Diseases

Currently open trials in the same condition.

Other Hospital do Rim e Hipertensão trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06116721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing